多布他胺对感染性休克患者的影响:一项回顾性全国性研究
Shotaro Aso1, Hiroki Matsui2, Kiyohide Fushimi3
1Department of Biostatistics & Bioinformatics, Graduate School of Medicine, The University of Tokyo.
Annals of clinical epidemiology
|March 20, 2024
概括
多布胺的使用并没有显著改变性休克患者的28天死亡率. 然而,多布他胺的使用与更长的住院时间有关,特别是在没有心血管疾病的患者中.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 败血栓冲击管理通常涉及解决hyperfusion.
- 多布胺对败血性休克死亡率的影响尚不清楚.
- 这项研究调查了多布他胺对败血症休克结果的影响.
研究的目的:
- 评估 dobutamine 管理与败血症休克患者28天死亡率之间的关联.
- 评估 dobutamine 对感染性休克病人的住院时间的影响.
- 用国家住院患者数据库分析多布他胺对败血症休克结果的影响.
主要方法:
- 日本诊断程序组合数据库的回顾性分析 (2010年7月至2016年3月).
- 纳入标准:患有败血性休克的成年人接受特定液体和血管压缩器复苏.
- 稳定反向概率权重分析比较了多布他胺和非多布他胺组之间的结果.
主要成果:
- 在接受多布胺 (n=1,259) 和不接受多布胺 (n=3,488) 的患者之间,28天全因死亡率没有显著差异.
- 多布他胺的使用与更长的住院时间 (长达3.8天) 有显著的关联.
- 亚组分析显示,心血管疾病患者或接受高剂量诺亚上腺素的患者与停留时间没有显著关联.
结论:
- 多布他胺在败血症休克患者的28天死亡率上没有显著的影响.
- 多布他胺的使用与住院时间的延长有关.
- 可能需要进一步的研究来澄清dobutamine在特定的败血症休克亚群中的作用.
更多相关视频
07:41Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
Published on: March 17, 2022
3.0K
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
3.3K
相关概念视频
01:22Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338
01:26Heart Failure Drugs: Inotropic Agents
584
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
584
01:19Depolarizing Blockers: Pharmocokinetics
325
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
325